stars 1 stars 2 stars 3

Droplet IV is a need-driven MedTech start-up founded by doctors and engineers. Droplet started in the BioMedical Design Novo Nordisk Foundation Fellowship Programme and and BioInnovation Institute. Problem: ≈20% of intravenous (IV) medicine is trapped as residual medicine in IV lines and never reaches the patient leading to significant underdosing. To mitigate this patient risk, nurses must spend time to flush each IV line manually. This is unrealistic and not scalable with the growing global nurse shortage. Solution: Droplet ensures that patients receive the full prescribed dose of medicine every time by automatically flushing IV lines. Market: There are globally more than 6B IV infusions annually. Value propositions of automatic IV line flushing by Droplet: 💧No underdosing by guaranteeing infusion of the full prescribed dose 💧Decreases the number of nurse tasks and reduces multitasking 💧Ensure golden standard IV treatment for all patients 💧Removes the cost of wasted medicine 💧Fights antibiotic resistance by removing antibiotics ending up in nature as waste and eliminating underdosing. Factors that drive antibiotic resistance As a company, we focus on creating a strong holistic company culture. Personal and professional learning is a priority in Droplet. As we normally say here in Droplet: Medicine belongs in patients - not in the trash! Please don't hesitate to get in touch should you have any questions. On behalf of everybody here at team Droplet 💧

Droplet IV Questions

Niklas Rädel is the Co-Founder and CTO of Droplet IV.

5 people are employed at Droplet IV.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users